Survival Based on Risk Status in Patients With Polycythemia Vera

Carole Miller, MD, director of the Cancer Institute at Ascension Saint Agnes, discusses the overall findings from the REVEAL study.

REVEAL is a phase 4, multicenter, non-interventional, non-randomized, prospective, observational study which enrolled patients aged 18 years or older with polycythemia vera (PV) at both academic and community practices.

According to Miller, patients had their quality of life measured using a myeloproliferative neoplasms symptom scale during clinical visits. Patients were enrolled over a 2-year period and ended up being followed 36 months from the date of the last patient enrollment.

Of the 2510 patients included, 244 patients died during the course of the study. Findings determined survival in the low-risk patients to be excellent while high-risk patients had the worst outcomes (97%, 86%). Patients who died had higher rates of comorbid disease compared to the patients who were alive at the completion of the study. In regard to causes of death, the most common was vascular complications and 33% hematologic malignancies.

Transcription:

0:08 | This survival in patients who are considered low-risk was excellent at 97% in the lowest patient versus 86% in the high-risk patients. Interestingly enough, the patients who were considered high-risk at enrollment, during the study, their survival was very similar to the low-risk patients at 94%.

0:43 | The worst group of patients that were put into the high-risk group at enrollment both by age and thromboembolic events where their survival was at 2% at a median of 4 years of follow-up, which is somewhat surprising. Given that the mean age at enrollment was only about 66 years, and we followed the patients for about 5 years overall, seeing a greater than 10% mortality rate overall at 4 years was quite surprising.